Background. A recent study has shown that preeclampsia is an important risk marker for end-stage renal disease (ESRD), but the underlying mechanisms are unclear. The present study investigated whether previous preeclampsia was associated with progression of established kidney disease. Material and methods. Data from the Norwegian Kidney Biopsy Registry and the Medical Birth Registry of Norway were linked. We included women who, after their last pregnancy, had had a representative kidney biopsy in 1988-2005. Women were followed up for the development of ESRD using data from the Norwegian Renal Registry. Baseline was set at the time of biopsy and Cox regression statistics were performed. Results. Of the 582 included women, 76 developed ESRD 3.9 ± 3.4 years (range, 0.08-16 years) after diagnosis. Mean age at first birth was 24.0 ± 4.8 years and at the time of diagnosis 41.3 ± 9.7 years. Women with clinically diagnosed preeclampsia in their first pregnancy had a relative risk of ESRD of 1.2 (95% CI, 0.63-2.4) and women with preterm birth had a relative risk of 2.1 (95% CI, 1.2-3.9). After extensive adjustments for clinical and histopathological variables at the time of diagnosis, the relative risks were 1.1 (95% CI, 0.50-2.6) and 2.4 (95% CI, 1.2-4.6), respectively. Compared to women with a first term birth without preeclampsia, women with term preeclampsia were diagnosed at a younger age (36 vs 42 years) and women with preterm birth without preeclampsia had a lower estimated glomerular filtration rate at diagnosis (48 vs 64 ml/min/1.73 m 2 ). Conclusion. In women with kidney disease diagnosed at kidney biopsy, previous preeclampsia does not seem to be a risk marker for progression to ESRD.
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Introduction
Recent studies have shown that women who previously have had preeclampsia have a three times increased risk of having a later kidney biopsy [1] and a four to five times increased risk of developing end-stage renal disease (ESRD) [2] . Furthermore, women without preeclampsia but with preterm birth also have an increased risk and those with both preeclampsia and preterm birth have an even higher risk of these outcomes [2] . The mechanisms underlying the increased risk of kidney disease after adverse pregnancy outcomes are, however, not clear [3] . The finding that preeclampsia was associated with the last stage of chronic kidney disease, ESRD, for up to 40 years after pregnancy suggests that preeclampsia may be associated with late kidney damage several years after pregnancy. The association also seemed to be similar for different types of kidney disease, both as diagnosed on kidney biopsy and as a cause of ESRD [1, 2] , suggesting a mechanism related to increased renal fibrosis (probably indirectly through other factors such as hypertension or proteinuria) rather than that specific renal damage of preeclampsia. The finding that 20-40% of women with preeclampsia have microalbuminuria 5 years after pregnancy [4] [5] [6] does, on the other hand, suggest that preeclampsia may exert some direct renal-damaging effect during pregnancy. For the further evaluation of preeclampsia as a risk factor for chronic kidney disease, it is important to characterize whether the effect is mainly a direct renal-damaging effect during pregnancy or a late effect.
In order to investigate whether preeclampsia and other adverse pregnancy outcomes were associated with late renal damage, we have, in the present study, investigated whether previous preeclampsia and other adverse pregnancy outcomes were associated with increased risk of progression of established chronic kidney disease. We included women who, after their last pregnancy, had a kidney biopsy in the period 1988-2005 in Norway. The women were followed up for the development of ESRD and our hypothesis was that previous preeclampsia and other adverse pregnancy outcomes would be associated with an increased risk of progression to ESRD.
Materials and methods
The patients were selected based on data from the Norwegian Kidney Biopsy Registry and the Medical Birth Registry of Norway. The Norwegian Kidney Biopsy Registry is a database that has registered extensive clinical and histopathological data at the time of biopsy for nearly all patients that have had a kidney biopsy in Norway (4.5 million inhabitants) since April 1988. All kidney biopsies that are recorded are reviewed by one nephropathologist at the registry, using the criteria given in the WHO monographs of renal disease [7, 8] ; consequently, consistent diagnoses are made for all patients. The Medical Birth Registry of Norway has registered extensive medical data reported by the attending midwife and/or doctor on all births in Norway since 1967 with a gestational age of at least 16 weeks [9] .
We linked data from the Kidney Biopsy Registry with data from the Medical Birth Registry and included all women who, after their last recorded birth (51 women who had had a birth after their kidney biopsies were not included), had had a representative kidney biopsy.
Patients were followed up using data from the Norwegian Renal Registry and the national Cause of Death Registry. We used unique national identification numbers to link data between the registries which provide complete national follow-up for the time period of interest. The Norwegian Renal Registry has registered data on all patients that have developed ESRD (defined as starting chronic dialysis treatment or undergoing renal transplantation) in Norway since 1980; these data were available through December 2005. The national Cause of Death Registry has registered time of death for all Norwegian citizens since 1965.
Variables in the Kidney Biopsy Registry
Standard clinical and laboratory tests were performed at the time of kidney biopsy. Estimated glomerular filtration rate (eGFR) was calculated using the four-variable MDRD equation [10] using the serum creatinine values recorded at the time of biopsy (race is not registered in the registry but virtually all women in Norway are white Caucasian and this was used for the calculation). Proteinuria had been registered as grams per 24 h, grams per litre and milligrams per millimole creatinine and as stix results. Most patients had proteinuria recorded as grammes per 24 h and the amount of proteinuria per 24 h for the other patients were calculated by multiplying grammes per litre with 1.5, milligrammes per millimole creatinine with 10 and, if data on proteinuria were still missing, by converting the urinary stix results to grams per 24 h (1+ on stix were set to 0.3 g/24 h, 2+ to 1.0 g/24 h and 3+ to 3.0 g/24 h). Systolic blood pressure (BP) was categorized into three categories: (i) <140 mmHg and no use of antihypertensive medications at the time of biopsy, (ii) 140 mmHg or more and <160 mmHg or use of antihypertensive medications and (iii) at least 160 mmHg with or without the use of antihypertensive medications. Diastolic BP was categorized using an identical strategy using 90 and 100 mmHg as cut-offs. Duration of known proteinuria, haematuria or renal failure had been recorded as <1 month (none in this study), 1-12 months, 1-10 years and 10 years or more.
As described previously, diagnostic criteria given in the WHO monographs of renal disease [7, 8] have been used for the classification of renal biopsies. In addition to being used as diagnostic criteria, as described above, arteriolosclerosis and interstitial fibrosis and inflammation were used as prognostic markers. For this use, arteriolosclerosis was recorded as present or absent and interstitial fibrosis and inflammation were present if there was at least mild focal interstitial fibrosis and interstitial inflammation.
Variables in the Medical Birth Registry
Criteria for preeclampsia used by the reporting midwives and obstetricians have been in accordance with the 1972 recommendations by the American College of Obstetrics and Gynecologists [11] : increased BP after 20 weeks' gestation (BP 140/90 mm Hg or greater or an increase in systolic BP of ≥30 mm Hg or in diastolic BP of ≥15 mm Hg from measurements made before 20 weeks of gestation) and proteinuria (0.3 g or more in a 24-h urine specimen or +1 or greater on urinary dipstick). Birth weight is measured shortly after birth; a weight below 2.5 kg was categorized as low birth weight. From 1967 through 1998, the estimation of gestational age was based on the last menstrual period, and from 1999 onwards, on routine ultrasonographic examination between gestational Weeks 17 and 20. Birth at a gestational age below 37 weeks was defined as preterm.
Statistical analysis
The main outcome in the present study was ESRD (as recorded in the Norwegian Renal Registry) and onset was defined as the date of starting dialysis treatment or undergoing renal transplantation. Women without ESRD were followed up until the end of December 2005 or date of death. Death prior to ESRD was treated as a censoring event. The main exposure variables in the present study were pregnancy outcomes of the women's births, especially for the first birth. We also separately analysed how clinical and histopathological data at the time of biopsy were associated with later development of ESRD. Estimates of relative risk were analysed by Cox regression analyses and baseline was set at the time of biopsy. Figures were prepared using Kaplan-Meier statistics.
For comparison of continuous variables, means ± standard deviations were given for normally distributed variables and t-tests were used for test of significance. Medians (25th-75th percentiles) were given for variables that did not have a normal distribution and Mann-Whitney tests were used for tests of significance. In order to determine significance of difference between proportions, chi-square statistics or Fisher's exact test were used. All tests of significance were two-tailed and P-values <0.05 were considered statistically significant. Analyses were performed using the statistical package SPSS 15 (SPSS Inc.).
Results
A total of 582 patients were included. Mean age at the time of biopsy was 41.3 ± 9.7 years (range, 19-75 years) and mean age at first birth was 24.0 ± 4.8 years (range, 15-44 years). Of the 582 included patients, 76 developed ESRD 3.9 ± 3.4 years (range, 0.08-16 years) after kidney biopsy. As shown in Table 1 , patients who developed ESRD had higher BP, serum creatinine, proteinuria and more interstitial fibrosis and inflammation and arteriolosclerosis. Whereas the different diagnostic groups were associated with different risks of progression to ESRD, the diagnostic groups were not differently associated with previous adverse pregnancy outcomes, with the exception that more women with focal and segmental glomerulosclerosis had had preeclampsia (Table 2) .
In Cox regression analyses, eGFR <60 ml/min/1.73 m 2 , proteinuria ≥1 g/24 h, hypertension, interstitial fibrosis and inflammation and arteriolosclerosis were associated with increased risk of progression to ESRD (Table 3) . After adjustments for age and categories of eGFR, low eGFR (only adjusted for age), high proteinuria, diastolic hypertension, known duration of renal disease of less than a year and interstitial fibrosis and inflammation were significant predictors of ESRD.
Adverse pregnancy outcomes and risk of ESRD
As shown in Table 1 , women who later developed ESRD more often had preterm birth in their first pregnancy, but they were of similar age and had not had preeclampsia (Table 4 and Figure 1 ). Preeclampsia, low birth weight offspring or the combined variable 'at least one adverse pregnancy outcome' was not significantly associated with ESRD. After partial and full adjustments, preterm birth remained a significant predictor of progression to ESRD whereas preeclampsia was not associated with later ESRD. In analyses where women who had the kidney biopsy within 10 years after her first birth were excluded (26% of the women, 25% of the women with later ESRD), preeclampsia in first pregnancy was associated with a relative risk of ESRD of 1.4 (95% CI, 0.60-3.3), preterm birth with a relative risk of 2.5 (95% CI, 1.3-5.0) and low birth weight offspring with a relative risk of 2.2 (95% CI, 1.1-4.3). After adjustments for age and eGFR, preterm birth was still a significant predictor (relative risk, 2.4 [95% CI, 1.2-4.9]). Of the 55 women with a preterm birth in the first pregnancy, 38% (21 women) had had a C-section compared to 9.8% for women with term births. Women who had had C-section at first birth had a non-significantly increased risk of ESRD of 1.7 (95% CI, 0.98-3.0). The increased risk of preterm birth was the same in women with and without C-section. Further adjusted for the significant variables in the adjusted analyses in Table 3 : proteinuria, diastolic BP, known duration of renal disease and interstitial fibrosis and inflammation. Adverse pregnancy outcomes were not differently associated with later ESRD for different diagnostic groups, but these analyses were inhibited by the low number of subjects in each group. The analyses presented in Table 4 were repeated for women who were diagnosed with chronic kidney diseases (that is, women with mesangioproliferative glomerulonephritis (GN), benign nephrosclerosis or chronic tubulointerstitial nephritis). In these analyses, the unadjusted relative risks were virtually identical to those presented in Table 4 with the exception that preterm birth was not associated with ESRD in the adjusted analyses.
We furthermore investigated whether adverse pregnancy outcomes in second pregnancy was associated with ESRD. Unfortunately, these analyses were inhibited by low numbers in subgroups of patients with adverse pregnancy outcomes and later ESRD. We, therefore, had to combine outcomes in first or second pregnancy and these analyses showed similar findings as described above (Table 4) .
Adverse pregnancy outcomes and characteristics at time of biopsy
In further analyses, we investigated whether the clinical characteristics at the time of biopsy differed between groups based on preeclampsia and preterm birth in first pregnancy. These analyses showed that women with a preterm birth without preeclampsia had lower eGFR, more arteriolosclerosis and more interstitial fibrosis and inflammation than women with a term birth without preeclampsia (Table 5) . Women with a term birth with preeclampsia were younger at the time of biopsy and had more often a known duration of renal disease of more than 1 year. Sub-analyses of women who were diagnosed with chronic kidney diseases at kidney biopsy showed that those who had had a term birth with preeclampsia were younger and had less interstitial fibrosis and inflammation than women with a term birth without preeclamp- sia. Women with a preterm preeclampsia were younger at the time of biopsy, had less often a second birth and had higher systolic BP at the time of biopsy.
Discussion
The present study unexpectedly demonstrated that previous preeclampsia was not associated with increased risk of progression towards ESRD after being diagnosed with kidney disease at kidney biopsy. Women who had had a preterm birth had, on the other hand, an increased risk of ESRD and this association remained significant after extensive adjustments for clinical and histopathological variables at the time of diagnosis. The study also showed that women who had had preeclampsia were diagnosed with kidney disease at a younger age than women who had not had preeclampsia and that women who had had preterm birth without preeclampsia had lower GFR, more interstitial fibrosis and inflammation and more arteriolosclerosis at the time of kidney biopsy than women with a term birth without preeclampsia.
The results of the present study were unexpected in light of the recent findings that women who have had preeclampsia have a three times increased risk of having a kidney biopsy [1] and a four to five times increased risk of developing ESRD [2] . In both these studies, previous preeclampsia was an important risk factor for any kidney disease and we, therefore, suspected that preeclampsia could be an important risk factor for progression of later kidney disease, irrespective of the primary renal disease. There are, however, several explanations that might account for the apparent discrepancy between this study and our previous studies.
First, as discussed in the introduction, preeclampsia may be associated with direct renal damage during pregnancy but not with later progression of kidney disease. The direct damage of preeclampsia may, for example, be glomerular sclerosis as a result of the widespread glomerular endotheliosis and subendothelial deposits seen during preeclampsia [12, 13] . Clinically, this might be detected through persistent microalbuminuria after pregnancy which seems to be present in 20-40% of women 5 years after they had preeclampsia [4] [5] [6] . A possible mechanism for later kidney damage after preeclampsia include persistent hypertension, endothelial dysfunction, obesity and other cardiovascular risk factors that have been shown to be more common in women with previous preeclampsia as well as being risk factors for chronic kidney disease [4, [14] [15] [16] [17] [18] . In the present study, women with or without previous preeclampsia had similar BP, a finding that may also explain the missing predictive effect of preeclampsia. Another possibility is a combination of the two mechanisms described above with a glomerular scar after the preeclamptic pregnancy that gradually progresses and leads to tubulointerstitial fibrosis over decades due to a toxic effect of filtered protein [19] or persistent hypertension. Although this latter explanation is appealing, it may be in conflict with the previous findings of an increased risk of any type of kidney disease after preeclampsia [1, 2] . A last possible explanation may be that some of the women with preeclampsia and later kidney disease in our previous studies [1, 2] may have had unrecognized kidney disease at the time of pregnancy, as suggested by some previous studies [20, 21] . The results of our previous studies were, however, unchanged after the exclusion of women with recognized kidney disease at the time of pregnancy. The results of the present study may, however, support such an explanation and further studies are needed to investigate this further.
Second, women with term preeclampsia were diagnosed with kidney disease at a younger age and more often had had a known duration of their kidney disease of more than 1 year. This may be a sign of better follow-up and earlier detection of chronic kidney disease in women with previous preeclampsia. This was further supported by a finding of less interstitial fibrosis and inflammation in women who were diagnosed with chronic kidney diseases who previously had had term preeclampsia compared to women who had not had preeclampsia. If women with previous preeclampsia received better follow-up and had their kidney disease detected earlier, it is a possibility that these women also could have received better renoprotective treatment. It is thus a possibility that the present retrospective study could have been confounded by better follow-up and treatment of women with previous preeclampsia. It should, however, be kept in mind that the findings indicating such an explanation for our findings are weak and that this, therefore, remains speculative. Nevertheless, it remains a possible explanation for the missing association between preeclampsia and progression to ESRD in the present study. Alternatively, women who have had preeclampsia may simply develop kidney disease at a younger age, in line with the previous studies showing an increased risk of kidney disease after preeclampsia [1, 2] .
The interpretation of the negative finding for preeclampsia in the present study is, however, complicated by the fact that preterm birth was associated with a doubling of the risk of progression to ESRD. Placental dysfunction might be an important feature of both preeclampsia and preterm birth [22] [23] [24] and thus represent a pathophysiological link between these two adverse pregnancy outcomes. Preeclampsia is, however, regarded as the most severe manifestation of placental dysfunction and the fact that preeclampsia was not associated with later progression of kidney disease suggests that there may be other explanations for the association. This is also suggested by our finding of a similarly increased risk in women with spontaneous preterm birth as in women with preterm birth with C-section or medical induction (results not shown). As cardiovascular risk factors such as obesity, smoking, diabetes and hypertension are associated with the risk of preeclampsia [25] [26] [27] , preterm birth [28] [29] [30] [31] [32] as well as chronic kidney disease [16] [17] [18] 33] , one explanation could be that these risk factors could be differentially associated with preterm birth, preeclampsia and later progression of chronic kidney disease. Smoking is, for example, a risk factor for preterm birth and chronic kidney disease but a protective factor for preeclampsia [27, 32] . The findings of more advanced kidney disease at the time of diagnosis in women with previous preterm birth also suggest that preterm birth may be associated with early kidney damage. We conclude that further investigations are needed to investigate the association between preterm birth and later progression of chronic kidney disease.
The main strengths of the present study are the full national inclusion and follow-up. The outcome, development of ESRD, is also highly clinically relevant. The Kidney Biopsy Registry provided women with diagnosed kidney disease and the opportunity to investigate whether clinical and histopathological variables at the time of biopsy modified the effect of adverse pregnancy outcomes (which they did). Although this design was well suited to answer our hypothesis, it inhibits generalizability of our findings to most women with chronic kidney disease who will not have a kidney biopsy. We chose to include all women with a representative biopsy and thus included women with a variety of acute and chronic kidney disease. In sub-analyses of a more homogenous sample of women, with the three most common diagnoses known to have a chronic course from the Kidney Biopsy Registry, namely, mesangioproliferative GN, benign nephrosclerosis and chronic tubulointerstitial nephritis, results were similar although previous preterm birth did not predict ESRD in these analyses. Furthermore, in any study with negative results, Type II statistical errors must be discussed. The previous studies of preeclampsia and risk of kidney disease had shown that preeclampsia was associated with a three to five times increased risk [1, 2] and power calculations have shown that the number of women included in the present study should be more than adequate to demonstrate an effect of that magnitude. We, therefore, believe that the present study was not underpowered to answer its hypothesis.
Conclusion
In conclusion, the present study has demonstrated that previous preeclampsia is not an important predictor of progression to ESRD in women with kidney disease diagnosed by kidney biopsy. Women who have had a preterm birth do, on the other hand, both have more severe kidney disease at the time of biopsy and an increased risk of progression to ESRD. Taken together with previous findings, this suggests that preeclampsia may be more strongly associated with renal damage during or shortly after pregnancy than with later renal damage. Preterm birth seems, on the other hand, to be an important risk marker also for later renal damage, but the explanation for this is unclear. More research is needed to better understand the mechanisms underlying the described associations between adverse pregnancy outcomes and later kidney disease.
